Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans

(2010) Lena Persson et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients

(2010) Bertrand Cariou et al.   ATHEROSCLEROSIS

Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients

(2010) P. Costet et al.   ATHEROSCLEROSIS

A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake

(2010) Yan G. Ni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

(2010) Jeffrey D. Browning et al.   JOURNAL OF LIPID RESEARCH

Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters

(2010) Bin Dong et al.   JOURNAL OF LIPID RESEARCH

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

(2010) Greg Welder et al.   JOURNAL OF LIPID RESEARCH

A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo

(2010) Nidhi Gupta et al.   PLoS One

PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia

(2009) Bertrand Cariou et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor

(2009) Christopher J. Duff et al.   BIOCHEMICAL JOURNAL

Healthy Individuals Carrying the PCSK9 p.R46L Variant and Familial Hypercholesterolemia Patients Carrying PCSK9 p.D374Y Exhibit Lower Plasma Concentrations of PCSK9

(2009) S. E. Humphries et al.   CLINICAL CHEMISTRY

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

(2009) Markey C. McNutt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis

(2009) S. A. Mousavi et al.   JOURNAL OF INTERNAL MEDICINE

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

(2009) Jason S. Troutt et al.   JOURNAL OF LIPID RESEARCH

A new method for measurement of total plasma PCSK9: clinical applications

(2009) Geneviève Dubuc et al.   JOURNAL OF LIPID RESEARCH

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

(2009) J. C. Y. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo

(2008) Robert J. Schmidt et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity†

(2008) Daping Fan et al.   BIOCHEMISTRY

The Cholesterol Absorption Inhibitor Ezetimibe Acts by Blocking the Sterol-Induced Internalization of NPC1L1

(2008) Liang Ge et al.   Cell Metabolism

Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment

(2008) G. Lambert et al.   CLINICAL CHEMISTRY

PCSK9 as a therapeutic target of dyslipidemia

(2008) Nabil G Seidah   EXPERT OPINION ON THERAPEUTIC TARGETS

Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9

(2008) Sanae Kourimate et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Plasma PCSK9 preferentially reduces liver LDL receptors in mice

(2008) Aldo Grefhorst et al.   JOURNAL OF LIPID RESEARCH

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

(2008) Janice Mayne et al.   Lipids in Health and Disease

Extracellular loop C of NPC1L1 is important for binding to ezetimibe

(2008) A. B. Weinglass et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

(2008) M. Frank-Kamenetsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cross-talk Between Statins and PPARα in Cardiovascular Diseases: Clinical Evidence and Basic Mechanisms

(2008) Réjane Paumelle et al.   TRENDS IN CARDIOVASCULAR MEDICINE

Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease

(2008) Guoqing Cao et al.   Endocrine Metabolic & Immune Disorders-Drug Targets